EP1368340B1 - Derives de piperazine agonistes du recepteur de la melanocortine - Google Patents

Derives de piperazine agonistes du recepteur de la melanocortine Download PDF

Info

Publication number
EP1368340B1
EP1368340B1 EP02714719A EP02714719A EP1368340B1 EP 1368340 B1 EP1368340 B1 EP 1368340B1 EP 02714719 A EP02714719 A EP 02714719A EP 02714719 A EP02714719 A EP 02714719A EP 1368340 B1 EP1368340 B1 EP 1368340B1
Authority
EP
European Patent Office
Prior art keywords
compound
formula
mmol
phenyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP02714719A
Other languages
German (de)
English (en)
Other versions
EP1368340A1 (fr
Inventor
Christopher Kelly Biggers
Karin Briner
Christopher William Doecke
Matthew Joseph Fisher
Larry Wayne Hertel
Vincent Lilly MSG Development Centre S.A. MANCUSO
Michael John Martinelli
John Philip Mayer
Paul Leslie Ornstein
Timothy Ivo Richardson
Jikesh Arvind Shah
Qing Shi
Zhipei Wu
Chaoyu Xie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of EP1368340A1 publication Critical patent/EP1368340A1/fr
Application granted granted Critical
Publication of EP1368340B1 publication Critical patent/EP1368340B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to melanocortin receptor agonists, and more particularly piperazine derivatives as melanocortin receptor agonists, which are useful for the treatment or prevention of diseases and disorders responsive to the activation of melanocortin receptors.
  • Pro-opiomelanocortin (POMC) derived peptides are known to affect food intake.
  • GPCRs G-protein coupled receptors
  • M-R melanocortin receptor
  • MC-1R Five MC-Rs have thus far been identified, and these are expressed in different tissues.
  • MC-1R was initially characterized by dominant gain of function mutations at the extension locus, affecting coat color by controlling phaeomelanin to eumelanin conversion through control of tyrosinase.
  • MC-1R is mainly expressed in melanocytes.
  • MC-2R is expressed in the adrenal gland and represents the ACTH receptor.
  • MC-3R is expressed in the brain, gut and placenta and may be involved in the control of food intake and thermogenesis.
  • MC-4R is uniquely expressed in the brain and its inactivation was shown to cause obesity.
  • MC-5R is expressed in many tissues including white fat, placenta and exocrine glands. A low level of expression is also observed in the brain. MC-5R knock out mice reveal reduced sebaceous gland lipid production (Chen et al., Cell , 91:789-798, 1997).
  • MC-4R appears to play a role in other physiological functions as well, namely controlling grooming behavior, erection and blood pressure.
  • Erectile dysfunction denotes the medical condition of inability to achieve penile erection sufficient for successful intercourse.
  • the term "impotence" is often times employed to describe this prevalent condition.
  • Synthetic melanocortin receptor agonists have been found to initiate erections in men with psychogenic erectile dysfunction (H. Wessells et al., "Synthetic Melanotropic Petide Initiates Erections in Men With Psychogenic Erectile Dysfunction: Double-Blind, Placebo Controlled Crossover Study," J. Urol., 160: 389-393, 1998).
  • Activation of melanocortin receptors of the brain appears to cause normal stimulation of sexual arousal.
  • Evidence for the involvement of MC-R in male and/or female sexual dysfunction is detailed in WO 00/74679.
  • Diabetes is a disease in which a mammal's ability to regulate glucose levels in the blood is impaired because the mammal has a reduced ability to convert glucose to glycogen for storage in muscle and liver cells. In Type I diabetes, this reduced ability to store glucose is caused by reduced insulin production.
  • Type II Diabetes or “non-insulin dependent diabetes mellitus” (NIDDM) is the form of diabetes, which is due to a profound resistance to insulin stimulating or regulatory effect on glucose and lipid metabolism in the main insulin-sensitive tissues, muscle, liver and adipose tissue. This resistance to insulin responsiveness results in insufficient insulin activation of glucose uptake, oxidation and storage in muscle and inadequate insulin repression of lipolysis in adipose tissue and of glucose production and secretion in liver.
  • Hyperinsulemia is associated with hypertension and elevated body weight. Since insulin is involved in promoting the cellular uptake of glucose, amino acids and triglycerides from the blood by insulin sensitive cells, insulin insensitivity can result in elevated levels of triglycerides and LDL which are risk factors in cardiovascular diseases.
  • the constellation of symptoms which include hyperinsulemia combined with hypertension, elevated body weight, elevated triglycerides and elevated LDL is known as Syndrome X.
  • the present invention relates to a compound of novel piperazine derivatives as melanocortin receptor agonists as shown formula I: or a pharmaceutically acceptable salts or stereoisomers thereof, wherein L and L 1 are independently: hydrogen or together oxo; T is: R is independently: hydrogen, hydroxy, cyano, nitro, halo, C 1 -C 8 alkyl, C 1 -C 8 alkoxy, C 1 -C 4 haloalkyl, (D)C(O)R 9 , (D)C(O)OR 9 , (D)C(O)SR 9 , (D)C(O)heteroaryl, (D)C(O)heterocyclyl, (D)C(O)N(R 9 ) 2 , (D)N(R 9 ) 2 , (D)NR 9 COR 9 , (D)NR 9 CON(R 9 ) 2 , (D)NR 9 C(O)OR 9 , (D)NR 9 C(R 9
  • the compounds of the present invention are useful in preventing or treating obesity or diabetes mellitus in a mammal comprising the administration of a therapeutically effective amount of the compound of formula I.
  • the compounds of the present invention are also useful in preventing or treating male or female sexual dysfunction in mammal, more specifically erectile dysfunction, comprising the administration of a therapeutically effective amount of the compound of formula I.
  • composition or formulation which comprises a pharmaceutical carrier and at least one compound of formula I or its pharmaceutically acceptable salts or stereoisomers thereof.
  • the present invention further includes a process of making a pharmaceutical composition or formulation comprising a compound of formula I or its pharmaceutically acceptable salt or stereoisomers thereof and a pharmaceutically acceptable carrier.
  • the present invention further includes a process of preparing a compound of formula I.
  • the present invention relates to melanocortin receptor agonists, and more particularly piperazine derivatives which are melanocortin receptor agonists.
  • the compounds of present invention are useful for the treatment or prevention of diseases and disorders responsive to the activation of melanocortin receptors, such as obesity, diabetes and sexual dysfunction including erectile dysfunction and female sexual dysfunction.
  • R 3 is phenyl optionally para-substituted with chloro, bromo, fluoro, iodo, methoxy, benzyloxy or methyl.
  • the preferred R 3 is phenyl para-substituted with chloro, fluoro or methoxy.
  • the preferred embodiment of the present invention provides a compound of formula II, or a pharmaceutically acceptable salts or stereoisomers thereof.
  • Yet another preferred embodiment of the present invention provides a compound of formula III, or a pharmaceutically acceptable salts or stereoisomers thereof.
  • Yet another preferred embodiment of the present invention provides a compound of formula IV, or a pharmaceutically acceptable salts or stereoisomers thereof.
  • Yet another preferred embodiment of the present invention provides a compound of formula V, or a pharmaceutically acceptable salts or stereoisomers thereof.
  • the most preferred compound of the present invention is the compound listed below:
  • a pharmaceutical composition or formulation which comprises a pharmaceutical carrier and at least one compound of formula I or its pharmaceutically acceptable salts or stereoisomers thereof.
  • the pharmaceutical composition and or formulation may optionally further include a second active ingredient selected from the group consisting of an insulin sensitizer, insulin mimetic, sulfonylurea, alpha-glucosidase inhibitor, HMG-CoA reductase inhibitor, sequestrant cholesterol lowering agent, beta 3 adrenergic receptor agonist, neuropeptide Y antagonist, phosphodiester V inhibitor, and an alpha 2 adrenergic receptor antagonist.
  • Yet another aspect of the present invention is a process of making a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula I or its pharmaceutically acceptable salt or stereoisomers thereof as recited above and a pharmaceutically acceptable carrier.
  • Yet another aspect of the present invention is the compounds of Formula I for use in a method of preventing or treating obesity or diabetes mellitus in mammal comprising the administration of a therapeutically effective amount of the compound of formula I.
  • Yet another aspect of the present invention is the compounds of Formula I for use in a method of preventing or treating male or female sexual dysfunction in mammal, more specifically the male or female sexual dysfunction, comprising the administration of a therapeutically effective amount of the compound of formula I.
  • Yet another aspect of the present invention is a process for preparing a compound of formula I, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein -CLL 1 -(CH 2 ) n -T is: wherein R 1 is hydrogen, C 1 -C 8 alkyl, Boc, CBZ, phenyl, FMOC or (C 1 -C 8 alkyl)phenyl; Q represents a moiety: and R , R 1 , R 3 , R 4 , R 10 , p and r are as defined with regard to Formula I. comprising the steps of:
  • Step (a) is 2-bromobenzaldehydes.
  • the catalyst in Step (a) is selected from the group consisting of: Pd(Ph 3 P) 2 Cl 2 , Pd(Ph 3 P) 4 Cl 2 , Pd(Ph 3 P) 4 , Pd(Ph 3 P) 2 Cl 2 /CuI, Pd(OAc) 2 /Ph 3 P-Bu 4 NBr, Pd(Ph 3 P) 4 Cl 2 /H 2 and Pd(OAc) 2 /P(O-tol) 3 ; and wherein the base in Step (a) is NR 3 wherein R is hydrogen or C 1 -C 8 alkyl.
  • Step (b) is selected from the group consisting of: benzylamine, alpha-methylbenzylamine and BocNH 2 .
  • Step (b) further comprises reducing of intermediate imine compound in the presence of reducing agent, the reducing agent being selected from the group consisting of: NaCNBH 3 , Na(OAc) 3 BH, NaBH 4 /H+, and a combination of Et 3 SiH and TFA in CH 3 CN or CH 2 Cl 2 .
  • the reducing agent being selected from the group consisting of: NaCNBH 3 , Na(OAc) 3 BH, NaBH 4 /H+, and a combination of Et 3 SiH and TFA in CH 3 CN or CH 2 Cl 2 .
  • Step (e) further comprises deprotecting or protecting of the compound of formula (4) at NR 1 .
  • Yet another aspect of the present invention is a process for preparing a compound of formula I, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein -CLL 1 -(CH 2 ) n -T is:
  • Q represents a moiety: R , R 1 , R 3 , R 4 , p and r are as defined with regard to Formula I; and each R 11 is independently: hydrogen or (C 1 -C 8 )alkyl; comprising the steps of
  • Yet another aspect of the present invention is a process for preparing a compound of formula I, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein -CLL 1 -(CH 2 ) n -T is:
  • Q represents a moiety: R , R 1 , R 3 , R 4 , p and r are as defined with regard to Fomula I; and each R 11 is independently: hydrogen or (C 1 -C 8 )alkyl; comprising the steps of:
  • alkyl refers to those alkyl groups of a designated number of carbon atoms of either a straight or branched saturated configuration.
  • alkyl includes, but are not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl and t-butyl, pentyl, hexyl, neopenyl, isopentyl and the like.
  • Alkyl as defined above may be optionally substituted with a designated number of substituents as set forth in the embodiment recited above.
  • alkenyl means hydrocarbon chain of a specified number of carbon atoms of either a straight or branched configuration and having at least one carbon-carbon double bond, which may occur at any point along the chain, such as ethenyl, propenyl, butenyl, pentenyl, vinyl, alkyl, 2-butenyl and the like. Alkenyl as defined above may be optionally substituted with designated number of substituents as set forth in the embodiment recited above.
  • haloalkyl is an alkyl group of indicated number of carbon atoms, which is substituted with one to five halo atoms selected from F, Br, Cl and I.
  • An example of a haloalkyl group is trifluoromethyl.
  • alkoxy represents an alkyl group of indicated number of carbon atoms attached through an oxygen bridge, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, tert-butoxy, pentoxy, and the like. Alkoxy as defined above may be optionally substituted with a designated number of substituents as set forth in the embodiment recited above.
  • cycloalkyl refers to a ring composed of 3 to 7 methylene groups, each of which may be optionally substituted with other hydrocarbon substituents.
  • examples of cycloalkyl includes, but are not limited to: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl, and the like. Cycloalkyl as defined above may be optionally substituted with a designated number of substituents as set forth in the embodiment recited above.
  • halo refers to fluoro, chloro, bromo and iodo.
  • haloalkyloxy represents a haloalkyl group of indicated number of carbon atoms attached through an oxygen bridge, such as OCF 3 .
  • Haloalkyloxy as defined above may be optionally substituted with a designated number of substituents as set forth in the embodiment recited above.
  • aryl refers to phenyl, naphthyl, anthracenyl, phenanthrenyl and the like which is optionally substituted with a designated number of substituents as set forth in the embodiment recited above.
  • heteroaryl refers to monocyclic or bieyclic aromatic ring of 5- to 10-carbon atoms containing from one to four heteroatoms selected from O, N, or S, and the heteroaryl being optionally substituted with a designated number of substituents as set forth in the embodiment recited above.
  • heteroaryl examples include furanyl, thienyl, thiazolyl, imidazolyl, isoxazoyl, oxazoyl, pyrazoyl, pyrrolyl, pyrazinyl, pyridyl, pyrimidyl, and purinyl, cinnolinyl, benzothienyl, benzotriazolyl, benzoxazolyl, quinoline, isoquinoline and the like.
  • heterocyclyl is defined as a monocyclic, bicyclic, or tricyclic ring of 5 to 14 carbon atoms which are saturated or partially saturated containing from one to four heteroatoms selected from N, O or S.
  • the "heterocycly” includes "nitrogen containing heterocyclyl,” which contains from one to four nitrogen atoms and optionally further contains one other heteroatom selected from O or S. Heterocyclyl as defined above may be optionally substituted with a designated number of substituents as set forth in the embodiment recited above.
  • a mammal as used in here includes a human and a warm-blooded animal such as a cat, a dog and the like.
  • compositions or “formulation”, as in pharmaceutical composition or formulation, is intended to encompass a product comprising the active ingredient(s), and the inert ingredient(s) that make up the carrier. Accordingly, the pharmaceutical compositions of the present invention encompass any composition made by admixing a compound of the present invention (a compound of formula I) and a pharmaceutically acceptable carrier.
  • pharmaceutical when used herein as an adjective means substantially non-deleterious to the recipient mammal.
  • unit dosage form refers to physically discrete units suitable as unitary dosages for human subjects and other non-human animals such as warm-blooded animals each unit containing a predetermined quantity of active ingredient (a compound of formula I) calculated to produce the desired therapeutic effect in association with a suitable pharmaceutical carrier.
  • treating includes its generally accepted meanings, i . e ., preventing, prohibiting, restraining, alleviating, ameliorating, slowing, stopping, or reversing the progression or severity of a pathological condition, or sequela thereof as described herein.
  • Erectile dysfunction is a disorder involving the failure of a male mammal to achieve erection, ejaculation, or both. Symptoms of erectile dysfunction include an inability to achieve or maintain an erection, ejaculatory failure, premature ejaculation, inability to achieve an orgasm. An increase in erectile dysfunction is often associated with age and is generally caused by a physical disease or as a side effect of drug treatment.
  • Female sexual dysfunction encompasses, without limitation, conditions such as a lack of sexual desire and related arousal disorders, inhibited orgasm, lubrication difficuldes, and vaginismus.
  • the compound of formula I may exist as a pharmaceutical base addition salt thereof.
  • Such salts include those derived from inorganic bases such as ammonium and alkali and alkaline earth metal hydroxides, carbonates, bicarbonates and the like, as well as salts derived from basic organic amines such as aliphatic and aromatic amines, aliphatic diamines, hydroxy alkamines, and the like.
  • the compound of formula I can also exist as a pharmaceutical acid addition salt.
  • Such salts include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, 2-butyne-1,4 dioate, 3-hexyne-2, 5-dioate, benzoate, chlorobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, xylenesulfonate, phenylacetate, phenylpropionate
  • Some of the compounds described herein may exist as tautomers such as ketoenol tautomers.
  • the individual tautomers as well as mixtures thereof are encompassed within the scope of the present invention.
  • Compounds of formula I are effective as melanocortin receptor modulators, particularly as agonists of the human MC-4 receptor.
  • melanocortin receptor agonists the compounds of formula I are useful in the treatment of diseases, disorders or conditions responsive to the activation of one or more of the melanocortin receptors including, but not limited to, MC-1, MC-2, MC-3, MC-4, and MC-5.
  • Diseases, disorders or conditions receptive to treatment with a MC-4 agonist include those mentioned above and those described in WO 00/74679, the teachings of which are herein incorporated by reference.
  • diseases, disorders or conditions receptive to treatment with a MC-4 agonist include obesity or diabetes mellitus, male or female sexual dysfunction, more specifically erectile dysfunction.
  • the compound of formula I is preferably formulated in a unit dosage form prior to administration. Accordingly the present invention also includes a pharmaceutical composition comprising a compound of formula I and a suitable pharmaceutical carrier.
  • the active ingredient (a compound of formula I) is usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier, which may be in the form of a capsule, sachet, paper or other container.
  • a carrier which may be in the form of a capsule, sachet, paper or other container.
  • the carrier serves as a diluent, it may be a solid, semisolid or liquid material which acts as a vehicle, excipient or medium for the active ingredient.
  • compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosol (as a solid or in a liquid medium), soft and hard gelatin capsules, suppositories, sterile injectable solutions and sterile packaged powders.
  • Suitable carriers, excipients, and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water syrup, methyl cellulose, methyl and propylhydroxybenzoates, talc, magnesium stearate and mineral oil.
  • the formulations can additionally include lubricating agents, wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents or flavoring agents.
  • the compositions of the invention may be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient.
  • the specific dose administered is determined by the particular circumstances surrounding each situation. These circumstances include, the route of administration, the prior medical history of the recipient, the pathological condition or symptom being treated, the severity of the condition/symptom being treated, and the age and sex of the recipient. Additionally, it would be understood that the therapeutic dosage administered can be determined by the physician in the light of the relevant circumstances.
  • an effective minimum daily dose of a compound of formula I is about 1, 5, 10, 15, or 20 mg.
  • an effective maximum dose is about 500, 100, 60, 50, or 40 mg.
  • the suitable dose may be determined in accordance with the standard practice in the medical arts of "dose titrating" the recipient, which involves administering a low dose of the compound initially and then gradually increasing the does until the desired therapeutic effect is observed.
  • the compounds may be administered by a variety of routes including the oral, rectal, transdermal, subcutaneous, topical, intravenous, intramuscular or intranasal routes.
  • Compounds of formula I may be used in combination with other drugs that are used in the treatment of the diseases or conditions for which compounds of formula I are useful. Such other drugs may be administered by a route and in an amount commonly used therefor, contemporaneously or sequentially with a compound of formula I.
  • a pharmaceutical composition containing such other drugs in addition to the compound of formula I is preferred.
  • the pharmaceutical compositions of the present invention include those that also contain one or more other active ingredients in addition to a compound of formula I. Examples of other active ingredients that may be combined with a compound of formula I, either administered separately or in the same pharmaceutical compositions, include but are not limited to:
  • the radioligand binding assay is used to identify competitive inhibitors of 125 I-NDP- ⁇ -MSH binding to cloned human MCRs using membranes from stably transfected human embryonic kidney (HEK) 293 cells.
  • HEK 293 cells transfected with human or rat melanocortinin receptors are grown either as adherent monolayers or suspension culture.
  • Monolayer cells are grown in roller bottle cultures at 37°C and 5% CO 2 /air atmosphere in a 3:1 mixture of Dulbecco's modified Eagle medium (DMEM) and Ham's F12 containing 25 mM L-glucose, 100 units/ml penicillin G, 100 microgram/ml streptomyocin, 250 nanogram/ml amphoterin B, 300 microgram/ml genticin and supplemented with 5% fetal bovine serum.
  • DMEM Dulbecco's modified Eagle medium
  • Ham's F12 containing 25 mM L-glucose, 100 units/ml penicillin G, 100 microgram/ml streptomyocin, 250 nanogram/ml amphoterin B, 300 microgram/ml genticin and supplemented with 5% fetal bovine serum.
  • the cell pellets are resuspended in 10 volumes of membrane preparation buffer (i.e., 1 g pellet to 10 ml buffer) having the following composition: 50 mM Tris pH 7.5 @ 4°C, 250 mM sucrose, 1 mM MgCl 2 , Complete® EDTA-free protease inhibitor tablet (Boehringer Mannheim), and 24 micrograms/ml DNase I (Sigma, St. Louis, MO).
  • the cells are homogenized with a motor-driven dounce using 20 strokes, and the homogenate is centrifuged at 38,000 x g at 4°C for 40 minutes.
  • the pellets are resuspended in membrane preparation buffer at a concentration of 2.5-7.5 mg/ml and 1 milliliter aliquots of membrane homogenates are quickly frozen in liquid nitrogen and then stored at -80°C.
  • Solutions of a compound of formula I 300 picomolar to 30 micromolar) or unlabelled NDP- ⁇ -MSH (1 picomolar to 100 nanomolar) are added to 150 microliters of membrane binding buffer to yield final concentrations (listed in parantheses).
  • the membrane binding buffer has the following composition: 25 mM HEPES pH 7.5; 10 mM CaCl 2 ; 0.3% BSA).
  • One hundred fifty microliters of membrane binding buffer containing 0.5-5.0 microgram membrane protein is added, followed by 50 nanomolar 125 I-NDP- ⁇ -MSH to final concentration of 100 picomolar.
  • fifty microliters of SPA beads (5 mg/ml) are added and the resulting mixture is agitated briefly and incubated for 10 hours at r.t.
  • Functional cell based assays are developed to discriminate agonists and antagonists.
  • Agonist Assay HEK 293 cells stably expressing a human melanocortin receptor (see e.g., Yang, et al., Mol-Endocrinol., 11 (3): 274-80, 1997) are dissociated from tissue culture flasks using a trypsin/EDTA solution(0.25%; Life Technologies, Rockville, MD). Cells are collected by centrifugation and resuspended in DMEM (Life Technologies, Rockville, MD) supplemented with 1% L-glutamine and 0.5% fetal bovine serum. Cells are counted and diluted to 4.5x10 5 /ml.
  • a compound of formula I is diluted in dimethylsulfoxide (DMSO) (3 x 10 -5 to 3 x 10 -10 M final concentrations) and 0.05 volume of compound solution is added to 0.95 volumes of cell suspension; the final DMSO concentration is 0.5%.
  • DMSO dimethylsulfoxide
  • luciferin solution 50 mM Tris, 1 mM MgCl 2 , 0.2 % Triton-X100, 5 mM DTT, 500 micromolar Coenzyme A, 150 micromolar
  • Luciferase activity is measured from the cell lysate using a Wallac Victor 2 luminometer.
  • the amount of lumen production which results from a compound of formula I is compared to that amount of lumens produced in response to NDP- ⁇ -MSH, defined as a 100% agonist, to obtain the relative efficacy of a compound.
  • the EC 50 is defined as the compound concentration that results in half maximal stimulation, when compared to its own maximal level of stimulation.
  • the compounds are prepared as 10mM and NDP-alpha-MSH (control) as 33.3 ⁇ M stock solutions in 100 % DMSO. These are serially diluted in 100 % DMSO. The compound plate is further diluted 1:200 in compound dilution buffer (HBSS-092, 1 mM Ascorbic Acid, 1 mM IBMX, 0.6% DMSO, 0.1% BSA). The final concentration range being 10 ⁇ M-100 pM for compound and 33.33 nM-0.3 pM for control in 0.5 % DMSO. Transfer 20 ⁇ l from this plate into four PET 96-well plates (all assays are performed in duplicate for each receptor).
  • compound dilution buffer HBSS-092, 1 mM Ascorbic Acid, 1 mM IBMX, 0.6% DMSO, 0.1% BSA.
  • the final concentration range being 10 ⁇ M-100 pM for compound and 33.33 nM-0.3 pM for control in 0.5 % DMSO. Transfer 20 ⁇
  • HEK 293 cells stably transfected with the MC3R and MC4R were grown in DMEM containing 10% FBS and 1%Antibiotic/Antimycotic Solution. On the day of the assay the cells were dislodged with enzyme free cell dissociation solution and resuspended in cell buffer (HBSS-092, 0.1% BSA, 10 mM HEPES) at 1 x e6 cells/ml. Add 40 ⁇ l of cells/well to the PET 96-well plates containing 20 microliter diluted compound and control. Incubate @ 37°C in a waterbath for 20 minutes. Stop the assay by adding 50 ⁇ l Quench Buffer (50 mM Na Acetate, 0.25% Triton X-100).
  • Quench Buffer 50 mM Na Acetate, 0.25% Triton X-100
  • Radioligand binding assays were run in SPA buffer (50mM Sodium Acetate, 0.1% BSA). The beads, antibody and radioligand were diluted in SPA buffer to provide sufficient volume for each 96-well plate. To each quenched assay well was added 100 microliter cocktail containing 33.33 microliter of beads, 33.33 microliter antibody and 33.33 microliter 125 I-cAMP. This was based on a final concentration of 6.3 mg/ml beads, 0.65 % anti-goat antibody and 61 pM of 125 I-cAMP (containing 25000-30000 CPM) in a final assay volume of 210 microliter. The plates were counted in a Wallac MicroBeta counter after a 12-hour incubation.
  • the data was converted to pmoles cAMP using a standard curve assayed under the same conditions.
  • the data was analyzed using Activity Base software to generate agonist potencies (EC50) and percent relative efficacy data to NDP-alpha-MSH.
  • Baseline and/or vehicle evaluations are conducted to determine how and if an animal will respond. Some animals have a long duration until the first response while others are non-responders altogether. During this baseline evaluation, latency to first response time, number and type of responses are recorded. The testing time frame is 15 minutes after the first response.
  • mice can be dosed by a number of routes of administration depending on the nature of the study to be performed.
  • the routes of administration includes intravenous (IV), intraperitoneal (IP), subcutaneous (SC) and intracerebral ventricular (ICY).
  • Rodent assays relevant to female sexual receptivity include the behavioral model of lordosis and direct observations of copulatory activity. There is also a urethrogenital reflex model in anesthetized spinally transected rats for measuring orgasm in both male and female rats. These and other established animal models of female sexual dysfunction are described in McKenna, et al., Am. J. Physiol ., (Regulatory Integrative Comp. Physiol 30):R1276-R1285, 1991; McKenna, et al., Pharm. Bioch. Behav., 40:151-156, 1991; and Takahashi, et al., Brain Res ., 359:194-207, 1985.
  • Preparation of the compounds of the present invention may be carried out via sequential or convergent synthetic routes.
  • the skilled artisan will recognize that, in general, the three domains of a compound of formula I are connected via amide bonds.
  • the B and C domains are optionally connected via a reduced or partially reduced amide bond (e.g., via reductive amination).
  • the skilled artisan can, therefore, readily envision numerous routes and methods of connecting the three domains via standard peptide coupling reaction conditions.
  • standard peptide coupling reaction conditions means coupling a carboxylic acid with an amine using an acid activating agent such as EDC, dicyclohexylcarbodiimide, and benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate in a inert solvent such as DCM in the presence of a catalyst such as HOBT.
  • an acid activating agent such as EDC, dicyclohexylcarbodiimide, and benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate
  • a catalyst such as HOBT.
  • CBZ, Boc and FMOC protecting groups are used extensively in the synthesis, and their removal conditions are well known to those skilled in the art.
  • removal of CBZ groups can he achieved by catalytic hydrogenation with hydrogen in the presence of a noble metal or its oxide such as palladium on activated carbon in a protic solvent such as ethanol.
  • removal of CBZ can also be achieved by treatment with a solution of hydrogen bromide in acetic acid, or by treatment with a mixture of TFA and dimethylsulfide.
  • Removal of Boc protecting groups is carried out in a solvent such as methylene chloride, methanol or ethyl acetate with a strong acid, such as TFA or HCl or hydrogen chloride gas.
  • the compounds of formula I when exist as a diastereomeric mixture, may be separated into diastereomeric pairs of enantiomers by fractional crystallization from a suitable solvent such as methanol, ethyl acetate or a mixture thereof.
  • a suitable solvent such as methanol, ethyl acetate or a mixture thereof.
  • the pair of enantiomers thus obtained may be separated into individual stereoisomers by conventional means by using an optically active acid as a resolving agent.
  • any enantiomer of a compound of the formula I may be obtained by stereospecific synthesis using optically pure starting materials or reagents of known configuration.
  • the compounds of the present invention can be prepared according to the procedure of the following schemes and examples, which may further illustrate details for the preparation of the compounds of the present invention.
  • the compounds illustrated in the examples are, however, not to be construed as forming the only genus that is considered as the present invention.
  • an appropriate A domain e.g., piperazine
  • B domain e.g., D-Boc-p-Cl-Phe-OH
  • EDC/HOBt e.g., D-Boc-p-Cl-Phe-OH
  • the coupled AB compound is then coupled to an appropriate C domain followed by deprotection of Boc group and salt formation.
  • C domain is not protected with Boc group, the final compound can be obtained without the deprotection step.
  • an appropriate A domain e.g., piperazine
  • an appropriate BC domain in the presence of HATU followed by deprotection of Boc group and salt formation.
  • BC domain is not protected with Boc group, the final compound can be obtained without the deprotection step.
  • an appropriate BC domain is coupled to an appropriate A domain in the presence of EDC/HOBT followed by deprotection of Boc group and salt formation.
  • C domain is not protected with Boc group, the final compound can be obtained without the deprotection step.
  • EDC/HOAT for coupling of A with Boc-B, EDC/HOAT, EDC/HOBT or DCC/HOBT can be used.
  • the starting material of Boc-protected piperazine (A domain) can be deprotected in the presence of TFA/CH 2 Cl 2 , HCl/EtOAc, HCl/dioxane, or HCl in MeOH/Et 2 O with or without a cation scavenger, such as dimethyl sulfide (DMS) before being subjected to the coupling procedure. It can be freebased before being subjected to the coupling procedure or in some cases used as the salt.
  • a cation scavenger such as dimethyl sulfide (DMS)
  • a suitable solvent such as CH 2 Cl 2 , DMF, THF or a mixture of the above solvents can be used for the coupling procedure.
  • Suitable base includes triethyl amine (TEA), diisopropyethyl amine (DIPEA), N-methymorpholine, collidine, or 2,6-lutidine. Base may not be needed when EDC/HOBt is used.
  • the reaction mixture can be diluted with an appropriate organic solvent, such as EtOAc, CH 2 Cl 2 , or Et 2 O, which is then washed with aqueous solutions, such as water, HCl, NaHSO 4 , bicarbonate, NaH 2 PO 4 , phosphate buffer (pH 7), brine or any combination thereof.
  • an appropriate organic solvent such as EtOAc, CH 2 Cl 2 , or Et 2 O
  • aqueous solutions such as water, HCl, NaHSO 4 , bicarbonate, NaH 2 PO 4 , phosphate buffer (pH 7), brine or any combination thereof.
  • the reaction mixture can be concentrated and then be partitioned between an appropriate organic solvent and an aqueous solution.
  • the reaction mixture can be concentrated and subjected to chromatography without aqueous workup.
  • Protecting group such as Boc or CBZ, FMOC, CF 3 CO and H 2 /Pd-C can be deprotected in the presence of TFA/CH 2 Cl 2 , HCl/EtOAc, HCl/ dioxane, HCl in MeOH/Et 2 O, NH3/MeOH, or TBAF with or without a cation scavenger, such as thioanisole, ethane thiol and dimethyl sulfide (DMS).
  • the deprotected amines can be used as the resulting salt or are freebased by dissolving in CH 2 Cl 2 and washing with aqueous bicarbonate or aqueous NaOH.
  • the deprotected amines can also be freebased by ion exchange chromatography.
  • the compounds of the present invention can be prepared as salt, such as TFA, hydrochloride or succinate salts by using known standard methods.
  • the A domains of the present invention may be prepared from commercially available starting materials via known chemical transformations.
  • the preparation of A domain of the compound of the present invention is illustrated in the reaction scheme below.
  • the "A domain" of the compounds of the present invention can be prepared by coupling halo-substituted aryl 1 (X-Q) with piperazines 2 in the presence of tris(dibenzylideneacetone) dipalladium (Pd 2 (dba) 3 ), 1,1'-Bi[(2-diphenylphosphines) naphthalene] (BINAP) and sodium t-butoxide (NaO t Bu) or cesium carbonate (Cs 2 CO 3 ) in an organic solvent such as toluene at a suitable temperature. More detailed examples of A Domain preparation are described below.
  • the "A domain" of the compounds of the present invention can be prepared by heating appropriately substituted fluoro-aryl compounds 4 and piperazines 2 neat or with an appropriate solvent and with or without an appropriate base.
  • the "A domain" of the compounds of the present invention can be prepared by heating 1-bromo-2-fluoro-benzene 6 with various alcohols (R 9 -OH) in the presence of NaH to give ortho-substituted bromobenzenes 7 which can then be subjected to Buchwald conditions as shown in Reaction Scheme 4 above.
  • the "A domain" of the compounds of the present invention can be prepared by heating 2-bromophenol 9 with various aryl and heteroaryl boronates (X-OH) in the presence of Cu(OAc) 2 and pyridine to give ortho-substituted bromobenzenes 10 which can then be subjected to Buchwald conditions.
  • X-OH aryl and heteroaryl boronates
  • the "A domain" of the compounds of present invention can be prepared by reducing the nitrile of (2-cyano-phenyl)-piperazine 12 to the corresponding benzyl amine 13 with either NaBH 4 and TFA or H 2 and Raney nickel.
  • Benzyl amine 13 can be transformed to other benzyl amine derivatives 14 using various methods known to the skilled artisan.
  • the "A domain" of the compounds of present invention can be prepared by hydrolyzing the nitrile of (2-cyano-phenyl)-piperazine 12 to the corresponding carboxylic acid 15 with KOH followed by reduction to benzyl alcohol 16 with BH 3 -THF.
  • Benzyl alcohol 16 can be transformed to benzyl amines 17 either using Mitsunobu conditions or by activating the alcohol as the mesylate followed by nucleophilic displacement.
  • the "A domain" of the compounds of present invention can be prepared from 1-Boc-4-(2-amino-phenyl)-piperazine 19 which is prepared from 4-(2-nitro-phenyl)-piperazine 18 by Boc protection followed by nitro reduction.
  • 1-Boc-4-(2-amino-phenyl)-piperazine 19 can be transformed to other aniline derivatives 20 using various methods known to the skilled artisan.
  • Sulfonamides 21 could be prepared from 1-Boc-4-(2-amino-phenyl)-piperazine 19 by reaction with various sulfonyl chlorides.
  • the resulting sulfonamides 21 could then be deprotonated with NaH or K 2 CO 3 in DMF followed by alkylation with various alkyl halides (R 9 X) to afford alkylated sulfonamides 22.
  • 1-Boc-4-(2-anaino-phenyl)-piperazine could also be acylated with various acid chlorides to give acetamides 23.
  • the acetamides 23 could be reduced with BH 3 -THF to give alkyl amines 24 which can be transformed to other amine derivatives 25 using various methods known to the skilled artisan.
  • the "A domain" of the compounds of present invention can be prepared by reducing the nitrile of (2-cyano-phenyl)-piperazine 12 to the corresponding aldehyde 26 with DIBAL.
  • Aldehyde 26 can be transformed to benzyl amines 27 by reductive amination with various amines including nitrogen containing heterocycles.
  • These benzyl amines 27 can be transformed to other amine derivatives using various methods known to the skilled artisan.
  • Aldehyde 26 can also be reacted with various organolithium reagents (including lithiated aryl and heteroaryl groups) to give alcohols 28.
  • the alcohol can be oxidized to give ketones 29 or removed by Barton deoxygenation to give 30.
  • a domain of the compounds of present invention can be prepared by treating 1-Boc-(2-hydroxy-phenyl)-piperazine 31 with a base and an alkyl halide (RX) or subjected to Mitsunobu conditions with R 9 OH to give ortho-substituted aryl piperazines 32.
  • RX alkyl halide
  • a domain of the compounds of present invention can be prepared by hydrolyzing the nitrile of (2-cyano-phenyl)-piperazine 12 to the corresponding carboxylic acid 15 with KOH followed by transformation to other carboxylic acid derivatives 33 using various methods known to the skilled artisan.
  • a domain of the compounds of present invention can be prepared by reacting the nitrile of (2-cyano-phenyl)-piperazine 12 with tributyltin azide to give tetrazoles 34.
  • the tetrazoles can be further transformed to 35 using various methods known to the skilled artisan.
  • the present invention also provides a novel process for preparing certain intermediates and/or compounds of the invention as shown in Reaction Schemes 12-14.
  • the isoindoline compounds of the present invention may be prepared from 2-halobenzaldehyde 1 or substituted analog thereof.
  • Preferred starting material is 2-bromobenzaldehyde or substituted analog thereof.
  • Various Heck coupling reagents and conditions were found suitable to effect the coupling reaction.
  • Suitable catalysts and ligands include Pd(OAc) 2 /PPh 3 , Pd(OAc)PPh 3 /BU 4 NBr, Pd(PPH 3 ) 2 Cl 2 /CUI, Pd(OAC) 2 /P(O-Tol) 3 .
  • Suitable solvent or solvent systems for the Heck coupling reaction include DMF, toluene and ethyl acetate. More preferred base is triethylamine.
  • Reductive amination of the aldehyde functionality of 2 to amines is accomplished in good yields by reaction with benzylamine or alpha-methylbenzylamine in acidic conditions, followed by in situ reduction of the incipient imines with NaCNBH 3 at about pH 5.
  • Other reducing agents including Na(OAc) 3 BH and NaBH 4 /H may also be used to effect reduction of the incipient imines.
  • the resulting amines immediately cyclized to the isoindoline compounds under the same acidic conditions for the reduction.
  • Direct preparation of compound 4 may also be effected by use of BocNH 2 instead of benzylamine in the reductive amination step. Screening of various reducing agents demonstrated that the combination of Et 3 SiH and TFA in CH 3 CN represents the preferred method for effecting reductive amination using BocNH 2 .
  • the N -Boc isoindolinecarboxylic acid 5 may also be prepared from 3 as the carbamate, by an intra-molecular Michael addition and ester hydrolysis. The resolution of the isoindolinecarboxylic acids 4 by crystallization afforded enantio-pure compounds 5.
  • the isoindole or other "C” domain piece is coupled to an "AB” coupled domain piece to form the compound of formula I.
  • m-tyrosine ester or analogs, including substituted analogs thereof may be esterified by forming the acid halide followed by nucleophilic displacement of halide by the alkoxy group from an alcohol, i.e., methanol or ethanol. Where thionyl chloride or other halide source is used the product may be isolated as the acid addition salt (2).
  • the resulting ester (2) is subjected to a Pictet-Spengler reaction by heating with a suitable ketone or aldehyde in refluxing conditions.
  • a suitable ketone or aldehyde in refluxing conditions.
  • an unsubstituted isoquinoline backbone (3) may be formed by employing formaldehyde in the pictet-Spengler reaction.
  • a gem-dimethyl substituted isoquinoline wherein R 11 is methyl may be formed by using acetone as the ketone source and solvent.
  • Other less reactive substituents may be substituted as the R 11 group for the practice of the present invention.
  • the product isoquinoline (3) may be isolated preferably as the acid addition salt. Where m-tyrosine is used as the starting material, the free hydroxyl group is removed first by protection/activation with a good leaving group such as, for example, reaction with triflic anhydride (trifluoromethane sulfonic anhydride) or methanesulfonic acid to form the triflate or mesylate in the presence of a base.
  • the triflate is a preferred group used to set up the compound (3) for deoxygenation because of the extra electron withdrawing effect of the trifluoromethane substituent.
  • the deoxygenation reaction is effected by hydrogenation at pressures of about 50psi.
  • the product (4) may be isolated as the acid addition salt.
  • the product (4) is hydrolyzed under basic conditions to afford the acid salt.
  • Suitable bases for the above hydrolysis include aqueous sodium hydroxide, potassium hydroxide and sodium lithium hydroxide.
  • the reaction is preferably performed in a mixture of aqueous and organic solvents. An exotherm during addition of base may be regulated (i.e., less than about 35°C) to avoid overheating or "runaway reactions.”
  • the reaction product may be isolated by aqueous work up. Alternatively, the entire mixture may be concentrated and washed with organic solvents to afford the desired product (6) after crystallization.
  • the product (6) is then reacted with a "B" domain substrate such as, for example, 4-chloro-D-phenylalanine as described previously and in the experimental section.
  • a "B” domain substrate such as, for example, 4-chloro-D-phenylalanine as described previously and in the experimental section.
  • the resulting "BC” combination product is then reacted with an "A” domain piece to form the respective compound of formula I.
  • the product (6) may be reacted with an "AB” domain combination product to afford a compound of formula I.
  • the isoquinoline product i.e., compound (3) or (5) including their N-protected analogs may be resolved by reaction with a resolving agent such as for example, L-tartaric acid, dehydroabietylamine or other resolving agents known to one of skill in the art.
  • a resolving agent such as for example, L-tartaric acid, dehydroabietylamine or other resolving agents known to one of skill in the art.
  • asymmetric analogs of product (6) may be prepared by using asymmetric starting materials.
  • L-DOPA may be used in place of m-tyrosine ester in reactions essentially similar to those described and illustrated in Reaction Scheme 13, and in the examples, to afford the asymmetric analog of compound (6).
  • Tetrahydroisoquinoline acetic acid derivatives may be prepared and utilized as shown in Reaction Scheme 14 below:
  • the compound of formula 10b may be protected as the compound 10c with a suitable protecting group (Pg) and then subjected to hydrogenation conditions including for example asymmetric hydrogenation to form a compound of formula 10d, which may be chiral (depending on hydrogenation conditions, i.e., asymmetric versus non-asymmetric hydrogenation).
  • the compound of formula 10d or stereoisomer thereof is reacted with a B-domain piece such as, for example, 4-chloro-D-phe to afford a BC piece (10e).
  • the compound of formula 10e is then reacted with an A-domain piece to afford a compound of formula I.
  • the details of the specific reaction steps are similar to or analogous to reactions taught herein, and in the experimental section.
  • one of skill in the art is aware of that such intermediate reactions as hydrolysis and deprotection may be necessary to achieve optimum yields in certain steps of the scheme as shown.
  • One of skill in the art is also aware of further common manipulations such as N-alkylation, or N-acylation, and alkylations on the benzene ring to afford other compounds of formula I.
  • 1-Boc-4-(2-aminomethyl-phenyl)-piperazine (0.75 g, 2.6 mmol) was dissolved in methylene chloride (20 mL), treated with DIPEA (2.3 mL, 13 mmol), and cooled to about 0°C.
  • Propionyl chloride (0.20 mL, 2.34 mmol) was added and the mixture was stirred for about 1 hour at 0°C and subsequently stirred overnight at r.t.
  • the mixture is diluted with ethyl acetate (400 mL), washed with water (45 mL), saturated aqueous sodium bicarbonate (45 mL) and brine (45 mL), and then dried over anhydrous sodium sulfate.
  • the title compound was prepared in the following procedure: About 0.40 g (1.37 mmol) of 1-Boc-4-(2-aminomethyl-phenyl)-piperazine, 0.11 ml of (1.51 mmol) propionic acid, 0.22g (1.64 mmol) of HOBt, 0.31g (1.64 mmol) of EDC, and 0.24 ml (1.37 mmol) of DIEA were mixed in 30 ml THF under nitrogen and stirred overnight at r.t. The reaction was concentrated to dryness and ethyl acetate was added. The mixture was washed with saturated bicarbonate and brine, and then dried with sodium sulfate.
  • 1-Boc-4-(2-Aminomethyl-phenyl)-piperazine (0.75g, 2.6 mmol) was dissolved in methylene chloride (20 mL). DIPEA (2.3 mL, 13 mmol) was added, and the mixture was cooled to about 0°C. The solution was treated with trimethylacetyl chloride (0.28 g, 0.28 mL, 2.3 mmol) and stirred for about 1 hour at 0°C. The solution was warmed to r.t. and stirred overnight.
  • the mixture was diluted with ethyl acetate (400 mL), washed with water (60 mL), saturated aqueous sodium bicarbonate (60 mL) and brine (60 mL) and then dried over anhydrous sodium sulfate.
  • the solution was concentrated under reduced pressure and purified via silica gel chromatography (80% ethyl acetate in hexanes) to afford a clear oil, which was subsequently stirred in neat TFA (5 mL) for about 1 hours. The solvent was evaporated under reduced pressure and the residue taken up in water (30 mL).
  • 1-Boc-4-(2-Aminomethyl-phenyl)-piperazine (0.47 g, 1.6 mmol) was dissolved in methylene chloride (20 mL). DIPEA (1.5 mL, 8.5 mmol) was added, and the mixture was cooled to about 0°C. The mixture was treated with benzoyl chloride (0.20 g, 0.16 mL, 1.4 mmol). The resulting mixture was stirred for about 1 hour at 0°C, and then warmed to r.t. and stirred overnight.
  • Step 1 1-Boc-4-(2-carboxy-phenyl)-piperazine To a solution of 1-(2-cyanophenyl)-piperazine (7.5 g, 40 mmol) in 100 mL of absolute ethanol was added 200 mL of 25% aqueous KOH. The solution was heated to reflux for about 48 hours and then cooled to about 0°C. The solution was acidified with 180 mL of 5 M HCl and then solid NaHCO 3 was added to bring the pH of the solution to about 10. After concentration in vacuo to remove 60 mL of solvent, dioxane (300 mL), NaHCO 3 (12.7 g, 120 mmol) and Boc 2 O (11.4 g, 52.2 mmol) were added.
  • dioxane 300 mL
  • NaHCO 3 (12.7 g, 120 mmol
  • Boc 2 O (11.4 g, 52.2 mmol
  • Step 2 1-Boc-4-(2-hydroxymethyl-phenyl)-piperazine
  • BH 3 -THF 120 mL of a 1 M solution in THF.
  • the cold bath was removed, and the solution stirred overnight.
  • the solution was cooled to about 0°C and then 60 mL of 2 M NaOH was added followed by EtOAc and brine. After separation, the aqueous solution was extracted with EtOAc (3x).
  • Step 3 To a solution of 1-Boc-4-(hydroxymethyl-phenyl)-piperazine (300 mg, 1.02 mmol, 1.0 eq.), 1,2,4 triazole (104 mg, 1.53 mmol, 1.5 eq.), triphenylphosphine (535 mg, 2.04 mmol, 2.0 eq.) and THF at 0°C under nitrogen was added DEAD (0.321 mL, 2.04 nmol, 2.0 eq.) slowly so that temperature of reaction does not rise above 10°C. After addition was completed, the ice bath was removed and the reaction mixture was stirred at r.t. overnight. Methanol was added and the mixture was stirred for about 15 minutes. The mixture was then concentrated.
  • DEAD 0.321 mL, 2.04 nmol, 2.0 eq.
  • 4-(2-cyano-3-trifluoromethyl-phenyl)piperazine was prepared in a manner similar to 4-(2-cyano-5-trifluoromethyl-phenyl)piperazine described above except that 2-fluoro-6-trifluoromethylbenzonitrile was used as the starting material.
  • 4-(2-cyano-3-trifluoromethyl-phenyl)piperazine (1.35 g, 5.29 mmol, 1.0 eq.) in dioxane (40 mL) was added a solution of DIBAL in heptane (1.0 M in heptane, 13.2 mL, 13.22 mmol, 2.5 eq.). The resulting mixture was stirred at r.t. for about 3 days.
  • N-(2-nitrophenyl)-piperazine (30 g, 145 mmol) and triethylamine (28.3 mL, 203 mmol) in 600 mL of CH 2 Cl 2 was added Boc 2 O (38 g, 174 mmol). After stirring overnight, the solution was washed with saturated aqueous sodium bicarbonate and brine, and then dried (Na 2 SO 4 ), filtered and concentrated to afford an orange oil. To a solution of the oil in 2 L of ethanol was added 6 g of 5% Pd/C.
  • the protected amino acid derivatives corresponding to the B and C domains are, in many cases, commercially available.
  • Other protected amino acid derivatives can be prepared by following known literature methods (See Williams, R. M. Synthesis of Optically Active ⁇ -Amino Acids, Pergamon Press: Oxford, 1989). The following provides the preparation of C domains.
  • Boc-D-Tic-OH (14.9g, 53.7mmol), methoxymethylamine hydrochloride (5.24g, 53.7mmol), EDC (11.3g, 59.1mmol), HOBT (7.98g, 59.1mmol), DIEA (9.83ml, 59.1mmol) and THF (500ml) were combined, and the resulting mixture was stirred for about 18 hours at r.t. under nitrogen. The reaction mixture was concentrated and the residue was taken up in ethyl acetate. The resulting mixture was washed with 1M HCl, saturated NaHCO 3 and brine, which was then dried via filtration through phase separator paper. Removal of solvent gives a residue, which was chromatographed on silica gel using (1:1 ethylacetate /hexane) to give about 12.3g of Boc-D-Tic-NMeOMe (Weinreb amide).
  • the compound from preparation Cl was deprotected with TFA in a manner similar to preparation 3C of Step A.
  • the Boc-protected compound (6.88g, 14.1mmol) was dissolved in 4M HCl/dioxane (230ml), and the resulting mixture was stirred at r.t. for about an hour. The mixture was concentrated in vacuo to give about 5.1g of the final compound.
  • Step A To a suspension of 4-Cl-D-Phe-OMe hydrochloride(40.4 g, 161.5 mmol) in DCM (250 mL) was added saturated aqueous sodium bicarbonate (250 mL), and the mixture was stirred at r.t. for about 1 hour. The organic portion was separated and the aqueous portion was extracted with DCM (2x). The combined organic portions were dried (Na 2 SO 4 ) and concentrated to dryness.
  • Step B To the ester from Step A (76.4 g, 161.5 mmol) in MeOH (760 mL) was added 1 N NaOH (242.0 mL, 242.0 mmol), and the mixture was heated at 50°C for 4 hours and then stirred for another 16 hours at r.t. After concentrating to dryness, the resulting residue was taken up in 500 mL of water and washed with diethyl ether (2x). The aqueous portion was acidified to pH 2 with 10% aqueous sodium bisulfate and extracted with EtOAc (4 x 200 mL). The combined organic extracts were dried (MgSO 4 ) and concentrated to dryness. The resulting solid was suspended in hexanes, filtered, and dried to afford about 67.7 g (91%) of the final compound. EIS-MS 457 [M-1].
  • the compounds of Examples 1-83 are prepared from an appropriate A domain piperazine by following a substantially similar coupling procedure as described in Procedures 1-5.
  • Examples 84-85 are prepared from an appropriate A domain piperazine by following a substantially similar coupling procedure as described in Procedures 1-5.
  • Example 86 is prepared by following a substantially similar coupling procedure as described in Procedure 2.
  • Examples 87-100 are prepared from an appropriate A domain piperazine by following a substantially similar coupling procedure as described in Procedures 1-5.
  • the compounds of Examples 101 and 102 are prepared from an appropriate A domain piperazine by following a substantially similar coupling procedure as described in Procedures 1-5.
  • Examples 103-146 are prepared from an appropriate A domain piperazine by following a substantially similar coupling procedure as described in Procedures 1-5.
  • Examples 150-151 are prepared from an appropriate A domain piperazine by following a substantially similar coupling procedure as described in Procedures 1-5.
  • the Examples 163 to 166 were prepared as follows.
  • the mixture of 4AB-2TFA salts or 4AB-HCl salts (Preparation 4AB) (1.0 eq.), N -Boc-substituted-D-Tic-OH or N-Boc-substituted-DL-Tic-OH (1.0 eq.), HATU (1.0 eq.) and DIEA (5.0-10.0 eq.) in DCM was stirred at r.t. overnight.
  • the mixture was partitioned between water and CH 2 Cl 2 .
  • the aqueous layer was extracted with CH 2 Cl 2 (2x).
  • the combined organic solution was dried over MgSO 4 , filtered and concentrated in vacuo .
  • the mixture purified by silica gel column using 10% MeOH in EtOAc to give N-Boc product.
  • the A domain piperazine of Preparation 11A was coupled to Boc-D-TIC-4-Cl-D-Phe-OH in a manner substantially similar to that describe in Coupling Procedure 2.
  • To a solution of the protected product (100 mg, 0.131 mmol) in 2 mL CH 2 Cl 2 was added 1 drop of H 2 O, and 1 mL of TFA. After stirring at r.t. for about 3 hours, the solution is azeotroped from heptane (3x).
  • To a solution of the residue in THF at 0°C was added 1 mL of HF-pyr.
  • Examples 172-174 are prepared from an appropriately substituted A domain piperazine by following a substantially similar coupling procedure as described in Coupling Procedures 1.
  • the mixture was cooled to rt, concentrated, and mixed with H 2 O (200 mL).
  • the organic solid was collected by filtration, and then applied to a plug of silica gel (25 g) (EtOAc/hexane 1:1) to give a dark yellow solid.
  • the solid was purified by crystallization (100 mL EtOAc bottom layer, 120 mL hexane top layer) to provide 17.57 g (70%) (100 % pure by NMR) of the first crop and 5.23 g (21%) (95% by NMR) of the second crop of 2a.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Hydrogenated Pyridines (AREA)
  • Indole Compounds (AREA)

Claims (19)

  1. Composé répondant à la formule I:
    Figure 03200001
    ou un sel, ou un stéréoisomère, pharmaceutiquement acceptable de ce composé, dans laquelle L et L1 représentent indépendamment : un atome d'hydrogène ou, ensemble, un groupe oxo;
    T représente :
    Figure 03200002
    Figure 03200003
    R représente indépendamment :
    un atome d'hydrogène, un groupe hydroxy, cyano, nitro, un atome d'halogène, un groupe alkyle en C1 à C8, alkoxy en C1 à C8, halogénoalkyle en C1 à C4, (D)C(O)R9, (D)C(O)OR9, (D)C(O)SR9, (D)C(O)hétéroaryle, (D)C(O)hétérocyclyle, (D)C(O)N(R9)2, (D)N(R9)2, (D)NR9COR9, (D)NR9CON(R9)2, (D)NR9C(O)OR9, (D)NR9C(R9)=N(R9), (D)NR9C(=NR9)N(R9)2, (D)NR9SO2R9, (D)NR9SO2N(R9)2, (D)NR9(CH2)nhétérocyclyle, (D)NR9(CH2)nhétéroaryle, (D)OR9, OSO2R9, (D)[O]q(cycloalkyle en C3 à C7), (D)[O]q(CH2)naryle, (D)[O]q(CH2)nhétéroaryle, (D)[O]q(CH2)n hétérocyclyle, dans lequel le groupe hétérocyclyle exclut un groupe hétérocyclyle contenant un atome d'azote unique lorsque q = 1, (D)SR9, (D)SOR9, (D)SO2R9, ou (D)SO2N(R9)2;
    dans lequel les groupes alkyle en C1 à C8, alkoxy en C1 à C8, cycloalkyle en C3 à C7, aryle, hétérocyclyle et hétéroaryle sont éventuellement substitués par un à cinq substituants indépendamment choisis parmi R8;
    R1 représente indépendamment :
    un atome d'hydrogène, un groupe CONH(alkyle en C1 à C8), alkyle en C1 à C8, (D)phényle, (D)cycloalkyle en C3 à C7 ou oxo, à condition que le groupe oxo ne soit pas attaché au même atome de carbone qui est attaché à un atome d'azote formant une liaison amide;
    R3 représente indépendamment : un groupe aryle ou thiényle;
    dans lequel les groupes aryle et thiényle sont éventuellement substitués par un à trois substituants choisis parmi le groupe constitué par :
    un groupe cyano, un atome d'halogène, un groupe alkyle en C1 à C8, (D)cycloalkyle en C3 à C7, alkoxy en C1 à C4, halogénoalkyle en C1 à C4 et halogénoalkyloxy en C1 à C4;
    R4 représente indépendamment:
    un atome d'hydrogène, un groupe alkyle en C1 à C8, C(O)R9, C(O)OR9, cycloalkyle en C3 à C7 ou (CH2)nO(alkyle en C1 à C8), dans lequel n vaut de 2 à 8;
    chaque R8 représente indépendamment :
    un atome d'hydrogène, un atome d'halogène, un groupe oxo, N(R10)2, alkyle en C1 à C8, (D)cycloalkyle en C3 à C7, halogénoalkyle en C1 à C4, alkoxy en C1 à C4, hétéroaryle, hydroxy, hétérocyclyle, dans lequel le groupe hétérocyclyle exclut un groupe hétérocyclyle contenant un atome d'azote unique, un groupe phényle, (D)COR9, (D)C(O)OR9, (D)OR9, (D)OCOR9, (D)OCO2R9, (D)SR9, (D)SOR9, ou (D)SO2R9;
    dans lequel un groupe aryle, hétéroaryle, hétérocyclyle, alkyle ou cycloalkyle est éventuellement substitué par un à trois substituants choisis parmi le groupe constitué par un groupe oxo, alkyle en C1 à C8, N(R10)2, OR10, SR10 et CO2R10;
    chaque R9 représente indépendamment :
    un atome d'hydrogène, un groupe alkyle en C1 à C8, halogénoalkyle en C1 à C4, (D)cycloalkyle en C3 à C7, (D)aryle, dans lequel le groupe aryle représente un groupe phényle ou naphtyle, (D)hétéroaryle ou (D)hétérocyclyle; dans lequel le groupe hétérocyclyle exclut un groupe hétérocyclyle contenant un atome d'azote unique ; et dans lequel le groupe aryle, hétéroaryle, hétérocyclyle, alkyle ou cycloalkyle est éventuellement substitué par un à trois substituants choisis parmi le groupe constitué par un groupe oxo, alkyle en C1 à C8, N(R10)2, OR10, SR10 et CO2R10;
    chaque R10 représente indépendamment :
    un atome d'hydrogène, un groupe alkyle en C1 à C8, C(O)alkyle en C1 à C8, aryle ou cycloalkyle en C3 à C7;
    chaque R11 représente indépendamment :
    un atome d'hydrogène, un groupe alkyle en C1 à C8, (D)aryle, (D)hétéroaryle, (CH2)nN(R8)2, (CH2)nNR8C(O)alkyle en C1 à C4, (CH2)nNR8SO2(alkyle en C1 à C4), (CH2)nSO2N(R8)2, (CH2)n[O]q(alkyle en C1 à C8), (CH2)n[O]q(CH2)nNR8COR8, (CH2)n[O]q(CH2)nNR8SO2R8, (CH2)n[O]qhétérocyclyle ou (CH2)n[O]q(alkyle en C1 à C8)hétérocyclyle; et dans lequel n vaut de 2 à 8;
    chaque R12 représente indépendamment :
    un atome d'hydrogène, un groupe alkyle en C1 à C8, (D)phényle, C(O)alkyle en C1 à C8, C(O)phényle, SO2(alkyle en C1 à C8) ou SO2-phényle;
    D est une liaison ou -(CH2)n-;
    n vaut de 0 à 8;
    p vaut de 0 à 5;
    q vaut de 0 à 1; et
    r vaut de 1 à 2.
  2. Composé selon la revendication 1, dans lequel R3 représente un groupe phényle éventuellement substitué en position para par un atome de chlore, de brome, de fluor, d'iode, un groupe méthoxy, benzyloxy ou méthyle.
  3. Composé selon la revendication 2, dans lequel R3 représente un groupe phényle substitué en position para par un atome de chlore, de fluor ou un groupe méthoxy.
  4. Composé selon l'une quelconque des revendications 1 à 3, dans lequel R4 représente un atome d'hydrogène.
  5. Composé selon l'une quelconque des revendications 1 à 4, dans lequel -(CH2)n-T représente :
    Figure 03230001
    où * indique un atome de carbone chiral ayant une configuration R ou S.
  6. Composé selon l'une quelconque des revendications 1 à 5, dans lequel L et L1 représentent ensemble un groupe oxo et l'atome de carbone chiral a une configuration R.
  7. Composé répondant à la formule II
    Figure 03240001
    ou un sel, ou un stéréoisomère, pharmaceutiquement acceptable de ce composé, dans laquelle R et p sont tels qu'ils ont été définis dans la revendication 1.
  8. Composé répondant à la formule III,
    Figure 03240002
    ou un sel, ou un stéréoisomère, pharmaceutiquement acceptable de ce composé, dans laquelle R et p sont tels qu'ils ont été définis dans la revendication 1.
  9. Composé répondant à la formule IV
    Figure 03250001
    ou un sel, ou un stéréoisomère, pharmaceutiquement acceptable de ce composé, dans laquelle R, R10 et p sont tels qu'ils ont été définis dans la revendication 1.
  10. Composé selon la revendication 9, dans lequel R10 représente un atome d'hydrogène ou un groupe alkyle en C1 à C8.
  11. Composé répondant à la formule V,
    Figure 03250002
    ou un sel, ou un stéréoisomère, pharmaceutiquement acceptable de ce composé, dans laquelle R et p sont tels qu'ils ont été définis dans la revendication 1.
  12. Composé choisi parmi le groupe constitué par :
    Figure 03260001
    Figure 03270001
  13. Composition pharmaceutique comprenant un support pharmaceutique et au moins un composé ou un sel, ou un stéréoisomère, pharmaceutiquement acceptable de ce composé selon l'une quelconque des revendications 1 à 12.
  14. Composition pharmaceutique selon la revendication 13, qui comprend en outre un second ingrédient actif choisi parmi le groupe constitué par un sensibilisateur d'insuline, un mimétique d'insuline, une sulfonylurée, un inhibiteur de l'alpha-glucosidase, un inhibiteur de la HMG-CoA réductase, un agent séquestrant réduisant le cholestérol, un agoniste du récepteur bêta 3 adrénergique, un antagoniste du neuropeptide Y, un inhibiteur du phosphodiester V, et un antagoniste du récepteur alpha 2 adrénergique.
  15. Utilisation d'un composé, d'un sel, ou d'un stéréoisomère, pharmaceutiquement acceptable selon l'une quelconque des revendications 1 à 12, dans la fabrication d'un médicament permettant de prévenir ou de traiter l'obésité chez un mammifère, ou de prévenir ou de traiter le diabète sucré chez un mammifère, ou de prévenir ou de traiter un dysfonctionnement sexuel mâle ou femelle chez un mammifère.
  16. Utilisation selon la revendication 15, où le dysfonctionnement sexuel mâle ou femelle est un dysfonctionnement érectile.
  17. Procédé permettant de préparer un composé répondant à la formule I:
    Figure 03280001
    ou un sel, ou un stéréoisomère, pharmaceutiquement acceptable de ce composé, dans laquelle -CLL1-(CH2)n-T représente :
    Figure 03280002
    dans lequel R1 représente un atome d'hydrogène, un groupe alkyle en C1 à C8, Boc, CBZ, phényle, FMOC ou (alkyle en C1 à C8)phényle;
    Q représente un résidu :
    Figure 03290001
    et
    R, R1, R3, R4, R10, p et r sont tels qu'ils ont été définis dans la revendication 1;
    le procédé comprenant les étapes de :
    a) faire réagir un composé ayant une formule structurelle 1,
    Figure 03290002
    avec CH2CH=C(O)ORa, dans lequel Ra représente un atome d'hydrogène ou un groupe alkyle en C1 à C8 et X représente un atome d'halogène, en présence d'un catalyseur et d'une base dans un solvant organique approprié, de façon à obtenir le composé répondant à la formule 2,
    Figure 03290003
    b) soumettre à une amination réductrice le composé répondant à la formule 2 en présence d'une amine en condition acide, de façon à obtenir un composé répondant à la formule 3,
    Figure 03300001
    c) procéder à une cyclisation du composé répondant à la formule 3 au moyen d'une addition de Michael, de façon à obtenir un composé répondant à la formule 4, ou ses stéréoisomères,
    Figure 03300002
    d) coupler le composé répondant à la formule 4, ou ses stéréoisomères, dans laquelle Ra du composé 4 représente H, avec un composé répondant à la formule 5,
    Figure 03300003
    dans laquelle Ra du composé 5 représente un groupe alkyle en C1 à C8, de façon à obtenir un composé répondant à la formule 6;
    Figure 03310001
    et
    e) coupler le composé répondant à la formule 6, dans laquelle Ra représente H, avec un composé ayant une structure
    Figure 03310002
    de façon à obtenir le composé répondant à la formule I.
  18. Procédé permettant de préparer un composé répondant à la formule I
    Figure 03310003
    ou un sel, ou un stéréoisomère, pharmaceutiquement acceptable de ce composé, dans laquelle -CLL1-(CH2)n-T représente :
    Figure 03310004
    Q représente un résidu :
    Figure 03320001
    R, R1, R3, R4, p et r sont tels qu'ils ont été définis dans la revendication 1 ; et
    R11 représente indépendamment: un atome d'hydrogène ou un groupe alkyle en C1 à C8 ;
    le procédé comprenant les étapes de :
    a) estérifier un composé répondant à la formule 1,
    Figure 03320002
    avec un alcool RaOH de façon à former un composé répondant à la formule 2
    Figure 03320003
    dans laquelle Ra représente un groupe alkyle en C1 à C4 ou (D)phényle;
    b) faire réagir un composé répondant à la formule 2 avec R11COR11 de façon à former un composé répondant à la formule 3,
    Figure 03320004
    dans laquelle R11 représente indépendamment un atome d'hydrogène ou un groupe alkyle en C1 à C4;
    c) faire réagir un composé répondant à la formule 3 avec un groupe d'activation de façon à former un composé répondant à la formule 4,
    Figure 03330001
    dans laquelle A représente un groupe d'activation ;
    d) désoxygéner le composé répondant à la formule 4 au moyen d'une hydrogénation de façon à obtenir un composé répondant à la formule 5,
    Figure 03330002
    e) faire éventuellement réagir le composé répondant à la formule 5 avec une base inorganique de façon à former un composé répondant à la formule 6,
    Figure 03330003
    dans laquelle HA représente un acide et M représente un cation monovalent ;
    f) résoudre le composé répondant à la formule 5 ou à la formule 6 de façon à obtenir un composé chiral répondant à la formule 7,
    Figure 03330004
    dans laquelle M représente un atome d'hydrogène et Ra' représente H ou Ra;
    g) coupler le composé répondant à la formule 7 avec un composé répondant à la formule 8,
    Figure 03340001
    de façon à obtenir un composé répondant à la formule 9,
    Figure 03340002
    et
    h) coupler le composé répondant à la formule 9 avec un composé ayant une formule
    Figure 03340003
    de façon à obtenir un composé répondant à la formule I.
  19. Procédé permettant de préparer un composé répondant à la formule I:
    Figure 03340004
    ou un sel, ou un stéréoisomère, pharmaceutiquement acceptable de ce composé, dans laquelle -CLL1-(CH2)n-T représente :
    Figure 03350001
    Q représente un résidu :
    Figure 03350002
    R, R1 , R3, R4, p et r sont tels qu'ils ont été définis dans la revendication 1 ; et
    R11 représente indépendamment: un atome d'hydrogène ou un groupe alkyle en C1 à C8;
    le procédé comprenant les étapes de :
    a) faire réagir un composé répondant à la formule 1:
    Figure 03350003
    dans laquelle X représente un atome d'halogène, et R11 représente indépendamment un atome d'hydrogène ou un groupe alkyle en C1 à C4, avec CNCH2CO2Ra dans lequel Ra représente un groupe alkyle en C1 à C8 ou un groupe benzyle de façon à obtenir un composé répondant à la formule 2:
    Figure 03360001
    b) protéger le composé répondant à la formule 2 de façon à former le composé répondant à la formule 3:
    Figure 03360002
    c) hydrogéner le composé répondant à la formule 3 de façon à obtenir un composé répondant à la formule 4:
    Figure 03360003
    d) coupler le composé répondant à la formule 4 dans laquelle Ra' représente un atome d'hydrogène ou Ra avec un composé répondant à la formule 5,
    Figure 03360004
    de façon à obtenir un composé répondant à la formule 6,
    Figure 03370001
    e) coupler le composé répondant à la formule 6 avec un composé ayant une formule
    Figure 03370002
    de façon à obtenir un composé répondant à la formule I.
EP02714719A 2001-01-23 2002-01-23 Derives de piperazine agonistes du recepteur de la melanocortine Expired - Lifetime EP1368340B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26347101P 2001-01-23 2001-01-23
US263471P 2001-01-23
PCT/US2002/000517 WO2002059108A1 (fr) 2001-01-23 2002-01-23 Derives de piperazine agonistes du recepteur de la melanocortine

Publications (2)

Publication Number Publication Date
EP1368340A1 EP1368340A1 (fr) 2003-12-10
EP1368340B1 true EP1368340B1 (fr) 2005-08-10

Family

ID=23001925

Family Applications (2)

Application Number Title Priority Date Filing Date
EP02714719A Expired - Lifetime EP1368340B1 (fr) 2001-01-23 2002-01-23 Derives de piperazine agonistes du recepteur de la melanocortine
EP02701922A Expired - Lifetime EP1370558B1 (fr) 2001-01-23 2002-01-23 Derives de piperazine et de piperidine en tant qu'agonistes du recepteur de la melanocortine

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP02701922A Expired - Lifetime EP1370558B1 (fr) 2001-01-23 2002-01-23 Derives de piperazine et de piperidine en tant qu'agonistes du recepteur de la melanocortine

Country Status (8)

Country Link
US (2) US7186715B2 (fr)
EP (2) EP1368340B1 (fr)
JP (2) JP2004523530A (fr)
AT (2) ATE301652T1 (fr)
CA (2) CA2431996A1 (fr)
DE (2) DE60205465T2 (fr)
ES (2) ES2247298T3 (fr)
WO (2) WO2002059108A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4076423A4 (fr) * 2019-12-19 2024-03-13 Casma Therapeutics, Inc. Modulateurs de trpml

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
SE9904723D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
CA2432988A1 (fr) 2001-01-23 2002-08-01 Cristina Garcia-Paredes Agonistes de recepteurs de melanocortine
ES2247298T3 (es) 2001-01-23 2006-03-01 Eli Lilly And Company Derivados de piperazina y piperidina como agonistas del receptor de melanocortina.
EP1368339A1 (fr) 2001-01-23 2003-12-10 Eli Lilly & Company Piperidines/piperazines substituees utilisees comme agonistes du recepteur de melanocortine
CA2438272A1 (fr) 2001-03-02 2002-10-10 John Macor Composes utiles comme modulateurs des recepteurs de la melanocortine et compositions pharmaceutiques renfermant ceux-ci
US6911447B2 (en) 2001-04-25 2005-06-28 The Procter & Gamble Company Melanocortin receptor ligands
US7115607B2 (en) * 2001-07-25 2006-10-03 Amgen Inc. Substituted piperazinyl amides and methods of use
US6977264B2 (en) 2001-07-25 2005-12-20 Amgen Inc. Substituted piperidines and methods of use
AU2002331064B2 (en) 2001-08-10 2007-08-23 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
US7456184B2 (en) 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7354923B2 (en) 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
UA81749C2 (uk) * 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
WO2003061660A1 (fr) * 2002-01-23 2003-07-31 Eli Lilly And Company Agonistes du recepteur de la melanocortine
US7026335B2 (en) 2002-04-30 2006-04-11 The Procter & Gamble Co. Melanocortin receptor ligands
AU2003230367A1 (en) * 2002-05-10 2003-11-11 Neurocrine Biosciences, Inc. Substituted piperazine as melanocortin receptors ligands
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
WO2004024720A1 (fr) 2002-09-11 2004-03-25 Merck & Co., Inc. Derives d'uree de piperazine utilises comme agonistes des recepteurs de melanocortine-4
TW200504033A (en) 2002-10-23 2005-02-01 Procter & Gamble Melanocortin receptor ligands
WO2004081643A1 (fr) * 2002-12-20 2004-09-23 Kaiser Aerospace & Electronics Corp. Reseau de lentilles a conversion de polarisation
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2004078717A1 (fr) 2003-03-03 2004-09-16 Merck & Co., Inc. Derives de piperazine acylee tenant lieu d'agonistes du recepteur de la melanocortine-4
US20060178403A1 (en) * 2003-03-07 2006-08-10 Neurocrine Biosciences, Inc. Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
WO2004083235A2 (fr) * 2003-03-19 2004-09-30 Exelixis Inc. Modulateurs de tie-2 et procedes d'utilisation
EP1460069A1 (fr) * 2003-03-20 2004-09-22 MyoContract Ltd. Dérivés substitués du cyclohexane et de la pipéridine comme modulateurs du récepteur de la melanocortine-4
EP1468999A1 (fr) * 2003-03-20 2004-10-20 MyoContract Ltd. Dérivés substitués de la pipéridine et la pipérazine comme modulateurs du récepteur de la melanocortine-4
CN1764458A (zh) 2003-03-26 2006-04-26 麦克公司 作为黑皮质素－4受体激动剂的双环哌啶衍生物
EP1644347A1 (fr) * 2003-06-20 2006-04-12 Arena Pharmaceuticals, Inc. Derives de n-phenyl-piperazine et methodes de prophylaxie ou de traitement de maladies associees au recepteur 5ht sb 2c /sb
ATE547404T1 (de) 2003-09-22 2012-03-15 Msd Kk Piperidinderivate
US20050119252A1 (en) * 2003-10-22 2005-06-02 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
US20050192286A1 (en) * 2003-10-22 2005-09-01 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
EP1538159A1 (fr) * 2003-12-05 2005-06-08 Santhera Pharmaceuticals (Schweiz) GmbH Dérivés de N-benzyl-lactam comme agonistes du récepteur melanocortine-4
CN100526301C (zh) * 2003-12-26 2009-08-12 卫材R&D管理有限公司 1,2-二(环式基)取代苯化合物
US7410971B2 (en) 2003-12-26 2008-08-12 Eisai R&D Management Co., Ltd. 1,2-di(cyclic)substituted benzene compounds
MY140489A (en) * 2003-12-26 2009-12-31 Eisai R&D Man Co Ltd 1,2-di (cyclic) substituted benzene compounds
US20060276465A1 (en) * 2003-12-26 2006-12-07 Eisai R&D Management Co., Ltd. 1,2-di(cyclic) substituted benzene compounds
EP1734963A4 (fr) 2004-04-02 2008-06-18 Merck & Co Inc Methode destinee a traiter des hommes presentant des troubles metaboliques et anthropometriques
SE0401465D0 (sv) 2004-06-08 2004-06-08 Carlsson A Research Ab New substituted piperdines as modulators of dopamine neurotransmission
US7851629B2 (en) 2004-06-08 2010-12-14 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission
ES2346452T3 (es) * 2004-06-08 2010-10-15 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Nuevas fenilpiperidinas/piperazinas disustituidas utilizadas como moduladores de la neurotransmision de la dopamina.
RU2366654C2 (ru) * 2004-06-08 2009-09-10 ЭнЭсЭйБи, ФИЛИАЛ АФ НЕУРОСЕРЧ СВИДЕН АБ, СВЕРИЙЕ Новые дизамещенные фенилпиперидины/пиперазины в качестве модуляторов допаминовой нейротрансмиссии
MXPA06013941A (es) 2004-06-08 2007-12-10 Neurosearch Sweden Ab Fenilpiperidinas disustituidas, novedosas, como moduladores de la neurotransmision de dopamina y serotonina.
CA2584831C (fr) 2004-10-13 2013-09-17 Neurosearch Sweden Ab Procede de synthese de 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine
TW200633721A (en) * 2004-12-14 2006-10-01 Shionogi & Co A pharmaceutical composition for treating constipation
CN101068798B (zh) * 2004-12-20 2010-05-12 卫材R&D管理有限公司 1-环丙基甲基-4-[2-(3,3,5,5-四甲基环己基)苯基]哌嗪的盐及结晶
BRPI0610580B8 (pt) 2005-05-30 2021-05-25 Banyu Pharma Co Ltd composto derivado de piperidina
US20070021433A1 (en) 2005-06-03 2007-01-25 Jian-Qiang Fan Pharmacological chaperones for treating obesity
MY144974A (en) * 2005-06-14 2011-11-30 Eisai R&D Man Co Ltd 1,2-di(cyclic) substituted benzene derivatives
JPWO2007018248A1 (ja) 2005-08-10 2009-02-19 萬有製薬株式会社 ピリドン化合物
WO2007024004A1 (fr) 2005-08-24 2007-03-01 Banyu Pharmaceutical Co., Ltd. Dérivé phénylpyridone
WO2007029847A1 (fr) 2005-09-07 2007-03-15 Banyu Pharmaceutical Co., Ltd. Dérivé de pyridone substitué aromatique bicylique
EP1940842B1 (fr) 2005-09-29 2012-05-30 Merck Sharp & Dohme Corp. Dérivés acylés de spiropipéridine en tant que modulateurs du récepteur de la mélanocortine-4
SE529246C2 (sv) 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
AU2006304305B2 (en) 2005-10-18 2010-04-01 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
JP2009512715A (ja) 2005-10-21 2009-03-26 ノバルティス アクチエンゲゼルシャフト レニン阻害剤と抗異脂肪血症剤および／または抗肥満症剤の組み合わせ
EP1944301A4 (fr) 2005-10-27 2012-01-04 Msd Kk Nouveau derive de benzoxathiine
ES2381205T3 (es) 2005-11-10 2012-05-24 Msd K.K. Derivado espiro aza-sustituido
US7601844B2 (en) 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
WO2007096186A1 (fr) * 2006-02-23 2007-08-30 Santhera Pharmaceuticals (Schweiz) Ag Dérivés de phénylpipéridine substituée servant de modulateurs du récepteur de la mélanocortine-4.
MX352516B (es) 2006-07-05 2017-04-06 Fibrotech Therapeutics Pty Ltd Compuestos terapeuticos.
US8173629B2 (en) 2006-09-22 2012-05-08 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20090247560A1 (en) 2006-09-28 2009-10-01 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
EP2019100A1 (fr) * 2007-07-19 2009-01-28 Santhera Pharmaceuticals (Schweiz) AG Dérivés substitués d'hétéroarylpipéridine en tant que modulateurs du récepteur de la mélanocortine-4
EP2020405A1 (fr) * 2007-07-30 2009-02-04 Santhera Pharmaceuticals (Schweiz) AG Dérivés substitués d'aryle ou d'hétéroarylpipéridine en tant que modulateurs du récepteur de la mélanocortine-4
EP2264026A4 (fr) 2008-03-06 2012-03-28 Msd Kk Dérivé d'alkylaminopyridine
WO2009119726A1 (fr) 2008-03-28 2009-10-01 萬有製薬株式会社 Dérivé de diarylméthylamide à activité antagoniste sur un récepteur d'hormone concentrant la mélanine
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
JPWO2009154132A1 (ja) 2008-06-19 2011-12-01 Ｍｓｄ株式会社 スピロジアミン−ジアリールケトオキシム誘導体
TWI433838B (zh) 2008-06-25 2014-04-11 必治妥美雅史谷比公司 作為趨化因子受體活性調節劑之六氫吡啶衍生物
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2319841A1 (fr) 2008-07-30 2011-05-11 Msd K.K. Dérivé de cycloalkylamine à noyaux fusionnés à (5 chaînons)-(5 chaînons) ou (5 chaînons) (6 chaînons)
EP2348857B1 (fr) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Nouveaux dérivés de benzimidazole cycliques utiles comme agents anti-diabétiques
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
UA99555C2 (en) 2008-11-12 2012-08-27 Элджи Лайф Саенсез Лтд. Melanocortin receptor agonists
EP2358200A4 (fr) 2008-11-17 2012-05-16 Merck Sharp & Dohme Amines bicycliques substituées pour le traitement du diabète
CA2768577A1 (fr) 2009-07-23 2011-01-27 Schering Corporation Composes d?oxazepine benzofusionnes en tant qu?inhibiteurs de la coenzyme-stearoyle a delta-9 desaturase
WO2011011506A1 (fr) 2009-07-23 2011-01-27 Schering Corporation Composés oxazépine spirocyclique en tant qu'inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase
CN102574843B (zh) 2009-10-22 2015-06-17 法博太科制药有限公司 抗纤维化剂的稠环类似物
US8476227B2 (en) 2010-01-22 2013-07-02 Ethicon Endo-Surgery, Inc. Methods of activating a melanocortin-4 receptor pathway in obese subjects
US9044606B2 (en) 2010-01-22 2015-06-02 Ethicon Endo-Surgery, Inc. Methods and devices for activating brown adipose tissue using electrical energy
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
WO2011137024A1 (fr) 2010-04-26 2011-11-03 Merck Sharp & Dohme Corp. Nouveaux inhibiteurs de spiropipéridine prolylcarboxypeptidase
EP2568812B1 (fr) 2010-05-11 2016-10-26 Merck Sharp & Dohme Corp. Inhibiteurs inédits de la prolylcarboxypeptidase
WO2011156246A1 (fr) 2010-06-11 2011-12-15 Merck Sharp & Dohme Corp. Nouveaux inhibiteurs de prolylcarboxypeptidase
US8642622B2 (en) 2010-06-16 2014-02-04 Bristol-Myers Squibb Company Piperidinyl compound as a modulator of chemokine receptor activity
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012100342A1 (fr) 2011-01-27 2012-08-02 Université de Montréal Pyrazolopyridine et dérivés de pyrazolopyrimidine en tant que modulateurs du récepteur de la mélanocortine-4
SG192941A1 (en) 2011-02-25 2013-09-30 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
TWI579272B (zh) 2011-12-08 2017-04-21 梯瓦製藥國際有限責任公司 普多比啶（ｐｒｉｄｏｐｉｄｉｎｅ）之氫溴酸鹽
AU2013216354B2 (en) 2012-02-02 2017-08-31 Idorsia Pharmaceuticals Ltd 4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives
AU2013243461A1 (en) 2012-04-04 2014-11-06 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for combination therapy
RU2015106909A (ru) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. Антидиабетические трициклические соединения
EP2746259A1 (fr) 2012-12-21 2014-06-25 Basf Se Composés de [1,2,4]triazole et d'imidazole substitués
EP2746260A1 (fr) 2012-12-21 2014-06-25 Basf Se Composés de [1,2,4]triazole et d'imidazole substitués
KR20150118158A (ko) 2013-02-22 2015-10-21 머크 샤프 앤드 돔 코포레이션 항당뇨병 비시클릭 화합물
WO2014139388A1 (fr) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Nouveaux dérivés d'indole utiles en tant qu'agents antidiabétiques
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
BR112015027164B1 (pt) 2013-06-05 2023-03-21 Shanghai Lumosa Therapeutics Co., Ltd Novos compostos com tripla atividade de trombólise, antitrombótica e neutralização de radical, e sua síntese, nanoestrutura e uso
BR112015030326A2 (pt) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
JP6330040B2 (ja) 2013-07-22 2018-05-23 イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ １−（ピペラジン−１−イル）−２−（［１，２，４］トリアゾール−１−イル）−エタノン誘導体
WO2015051496A1 (fr) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Composés tricycliques antidiabétiques
AR099789A1 (es) 2014-03-24 2016-08-17 Actelion Pharmaceuticals Ltd Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina
KR102431436B1 (ko) 2014-08-29 2022-08-10 테스 파마 에스.알.엘. α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제
US10080884B2 (en) 2014-12-29 2018-09-25 Ethicon Llc Methods and devices for activating brown adipose tissue using electrical energy
US10092738B2 (en) 2014-12-29 2018-10-09 Ethicon Llc Methods and devices for inhibiting nerves when activating brown adipose tissue
AR103399A1 (es) 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3
PL3245203T3 (pl) 2015-01-15 2019-05-31 Idorsia Pharmaceuticals Ltd Pochodne hydroksyalkilopiperazyny jako modulatory receptora cxcr3
CN105348204B (zh) * 2015-11-18 2018-09-14 乳源瑶族自治县大众药品贸易有限公司 1-杂环基-2-(杂芳基硫基)苯衍生物及其使用方法和用途
CN105294554B (zh) * 2015-11-18 2017-11-07 乳源瑶族自治县大众药品贸易有限公司 苯基哌嗪衍生物及其使用方法和用途
CN105461635B (zh) * 2015-11-18 2018-06-08 乳源瑶族自治县大众药品贸易有限公司 苯基哌嗪衍生物及其使用方法和用途
WO2018069532A1 (fr) 2016-10-14 2018-04-19 Tes Pharma S.R.L. Inhibiteurs de la semialdéhyde décarboxylase de l'acide alpha-amino-bêta-carboxymuconique
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298B1 (fr) 2016-12-20 2026-03-11 Merck Sharp & Dohme LLC Composés de spirochromane antidiabétiques
JP7185631B2 (ja) 2017-02-03 2022-12-07 サータ セラピューティクス プロプライエタリー リミテッド 抗線維化化合物
AR117122A1 (es) 2018-11-20 2021-07-14 Tes Pharma S R L INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
EP3821947A1 (fr) * 2019-11-13 2021-05-19 Libra Therapeutics, Inc. Agonistes heterocycliques de trpml1
AR129265A1 (es) 2022-05-12 2024-08-07 Syngenta Crop Protection Ag Compuestos de alcoxi-heteroaril-carboxamida o tioamida
WO2024033374A1 (fr) 2022-08-11 2024-02-15 Syngenta Crop Protection Ag Nouveaux composés arylcarboxamide ou arylthioamide
WO2024089216A1 (fr) 2022-10-27 2024-05-02 Syngenta Crop Protection Ag Nouveaux composés hétéroaryl-carboxamides contenant du soufre
JP2026500298A (ja) 2022-12-15 2026-01-06 シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト 殺有害生物剤として有用である新規な二環式カルボキサミド化合物
AR131541A1 (es) 2023-01-07 2025-04-09 Syngenta Crop Protection Ag Compuestos de carboxamida novedosos
WO2025032129A1 (fr) 2023-08-08 2025-02-13 Syngenta Crop Protection Ag Nouveaux composés d'aminoindane et d'aminotétraline
WO2025104032A1 (fr) 2023-11-14 2025-05-22 Syngenta Crop Protection Ag Nouveaux composés carboxamides
WO2025109114A1 (fr) 2023-11-24 2025-05-30 Syngenta Crop Protection Ag Nouveaux composés de carboxamide
WO2025149637A1 (fr) 2024-01-12 2025-07-17 Syngenta Crop Protection Ag Nouveaux composés de carboxamide
PY2501648A (es) 2024-01-12 2025-10-31 Syngenta Crop Protection Ag Nuevos compuestos de carboxamida
WO2026008750A1 (fr) 2024-07-05 2026-01-08 Syngenta Crop Protection Ag Nouveaux composés carboxamides

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994013696A1 (fr) 1992-12-11 1994-06-23 Merck & Co., Inc. Spiro-piperidines et homologues favorisant la liberation de l'hormone de croissance
EP1076649A4 (fr) 1998-04-28 2010-06-02 Trega Biosciences Inc Composes a base d'isoquinoline tenant lieu de ligands de recepteurs de melanocortine et procedes d'utilisation
WO1999064002A1 (fr) 1998-06-11 1999-12-16 Merck & Co., Inc. Derives de spiropiperidine en tant qu'agonistes des recepteurs de la melanocortine
US6294534B1 (en) 1998-06-11 2001-09-25 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
CA2377369A1 (fr) 1999-06-04 2000-12-14 Merck & Co., Inc. Piperidines substituees en tant qu'agonistes du recepteur de melanocortine-4
WO2001070708A1 (fr) 2000-03-23 2001-09-27 Merck & Co., Inc. Piperidines substituees en tant qu'agonistes du recepteur de la melanocortine
JP2003527444A (ja) 2000-03-23 2003-09-16 メルク エンド カムパニー インコーポレーテッド メラノコルチン受容体アゴニストとして作用するスピロピペリジン誘導体
JP2004506687A (ja) 2000-08-23 2004-03-04 メルク　エンド　カムパニー　インコーポレーテッド メラノコルチン受容体作働薬としての置換ピペリジン類
EP1368339A1 (fr) 2001-01-23 2003-12-10 Eli Lilly & Company Piperidines/piperazines substituees utilisees comme agonistes du recepteur de melanocortine
CA2432988A1 (fr) 2001-01-23 2002-08-01 Cristina Garcia-Paredes Agonistes de recepteurs de melanocortine
ES2247298T3 (es) * 2001-01-23 2006-03-01 Eli Lilly And Company Derivados de piperazina y piperidina como agonistas del receptor de melanocortina.
CA2438272A1 (fr) 2001-03-02 2002-10-10 John Macor Composes utiles comme modulateurs des recepteurs de la melanocortine et compositions pharmaceutiques renfermant ceux-ci
US7115607B2 (en) * 2001-07-25 2006-10-03 Amgen Inc. Substituted piperazinyl amides and methods of use

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4076423A4 (fr) * 2019-12-19 2024-03-13 Casma Therapeutics, Inc. Modulateurs de trpml

Also Published As

Publication number Publication date
US7186715B2 (en) 2007-03-06
WO2002059108A8 (fr) 2003-11-06
JP2004523530A (ja) 2004-08-05
EP1370558B1 (fr) 2005-08-24
US7291619B2 (en) 2007-11-06
DE60205465T2 (de) 2006-04-20
WO2002059117A1 (fr) 2002-08-01
CA2431996A1 (fr) 2002-08-01
DE60205727D1 (de) 2005-09-29
ATE301652T1 (de) 2005-08-15
WO2002059117A8 (fr) 2003-11-06
DE60205727T2 (de) 2006-06-29
WO2002059108A1 (fr) 2002-08-01
US20040082590A1 (en) 2004-04-29
DE60205465D1 (de) 2005-09-15
JP2004523529A (ja) 2004-08-05
ES2246390T3 (es) 2006-02-16
EP1370558A1 (fr) 2003-12-17
ES2247298T3 (es) 2006-03-01
EP1368340A1 (fr) 2003-12-10
US20040092507A1 (en) 2004-05-13
CA2432985A1 (fr) 2002-08-01
ATE302773T1 (de) 2005-09-15

Similar Documents

Publication Publication Date Title
EP1368340B1 (fr) Derives de piperazine agonistes du recepteur de la melanocortine
US7157463B2 (en) Substituted piperidines/piperazines as melanocortin receptor agonists
EP1469851B1 (fr) Agonistes du recepteur de la melanocortine
US7169777B2 (en) Melanocortin receptor agonists
JP2004524297A5 (fr)
MXPA01000150A (es) Compuestos de tetrahidroisoquinolina como agonistas/antagonistas de estrogeno.
EP0442878A1 (fr) Derives de tryptophan utilises comme antagonistes cck
JP2008534534A (ja) Ｍｍｐ阻害剤としての置換テトラヒドロイソキノリン、関連する製造法及び医薬としての使用
AU2002246969A1 (en) Melanocortin receptor agonists
AU2002235322A1 (en) Piperazine- and piperidine-derivatives as melanocortin receptor agonists
AU2002235323A1 (en) Substituted piperidines/piperazines as melanocortin receptor agonists
AU2003202852A1 (en) Melanocortin receptor agonists
AU2002235324A1 (en) Melanocortin receptor agonists
WO2004113302A1 (fr) 6,8-dialcoxy-1,2,3,4-tetrahydro-1h-isoquinolines n-substitutees utilisees en tant que modulateurs des canaux potassiques
JP2000191615A (ja) 芳香族アミン誘導体、その製造法および剤

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030825

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17Q First examination report despatched

Effective date: 20040126

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050810

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050810

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050810

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050810

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050810

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050810

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050810

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60205465

Country of ref document: DE

Date of ref document: 20050915

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20051110

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20051110

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20051110

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060110

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060123

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060131

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060131

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2246390

Country of ref document: ES

Kind code of ref document: T3

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20060511

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20080121

Year of fee payment: 7

Ref country code: GB

Payment date: 20071212

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20080131

Year of fee payment: 7

Ref country code: IT

Payment date: 20080119

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20080107

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050810

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20090123

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090801

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20091030

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090123

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20090124

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090124

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090202

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090123